The importance of preoperative topical non-steroidal antiinflammatory agents in cataract surgery- an open label prospective randomised comparative study
Abstract
Introduction: Intraoperative miosis is a problem which can lead to various complications that may adversely affect the outcome of cataract surgery. Topical non-steroidal anti-inflammatory drugs (NSAIDs) have been found to be helpful in reducing the intraoperative miosis. We tried to compare the effectiveness of two such molecules bromfenac and nepafenac.
Objective: To compare the effectiveness of topical bromfenac (0.09%) and nepafenac (0.1%) in maintaining mydriasis and controlling immediate post-operative inflammation in cataract surgery.
Methods: This is a prospective, randomised, open-label, comparative study of patients with senile cataract posted for cataract extraction and intra-ocular lens (IOL) implantation. The patients were randomised into 3 groups: topical moxifloxacilin 0.5% alone (control group or group A), topical bromfenac 0.09% + moxifloxacilin 0.5% (group B) and topical nepafenac 0.1% + moxifloxacilin 0.5% (group C). The drops were started one day before surgery. Mean pupil diameter was measured before starting surgery and after implanting IOL. Slit lamp examination was done on first postoperative day to look for anterior chamber reaction. The values were compared among the 3 groups.
Results: The total loss of mean pupillary diameter was significant (p < 0.0001) in control group (25.87%) as compared to bromfenac (3.51%) and nepafenac (3.81%) group. Post-operative inflammation was significantly less (p <0.0001) in bromfenac and nepafenac group as compared to that of control group. Loss of mydriasis and post-operative inflammation was similar in both bromfenac and nepafenac group.
Conclusion: Both bromfenac and nepafenac given topically prior to cataract surgery are equally effective in maintaining mydriasis during surgery as well as in controlling immediate postoperative inflammation.
Downloads
References
Khairallah M, Kahloun R, Bourne R, Limburg H, Flaxman SR, Jonas JB, et al. Number of people blind or visually impaired by cataract worldwide and in world regions, 1990 to 2010. Invest Ophthalmol Vis Sci. 2015; 56 (11):6762-6769. doi: https://doi.org/10.1167/iovs.15-17201.
Chen L, Yang G and Grosser T. Prostanoids and inflammatory pain. Prostaglandins Other Lipid Mediat. 2013;104-105:58-66.doi: https://doi.org/10.1016/j.prostaglandins.2012.08.006
Colin J. The Role of NSAIDs in the Management of postoperative ophthalmic Inflammation. Drugs. 2007; 67(9):1291-308. doi: https://doi.org/10.2165/00003495-200767090-00004
Ahuja M, Dhake A.S, Sharma S.K and Majumdar D.K. Topical ocular delivery of NSAIDs. Am Asso Pharm Sciences J. 2008; 10(2): 229-241.doi: https://doi.org/10.1208/s12248-008-9024-9
Kim SJ, Flach AJ, Jampol LM. Nonsteroidal anti-inflammatory drugs in ophthalmology. Surv Ophthalmol. 2010; 55 (2): 108-133. doi: https://doi.org/10.1016/j.survophthal.2009.07.005.
Schalnus R. Topical nonsteroidal anti-inflammatory therapy in ophthalmology. Ophthalmologica. 2003; 217 (2): 89-98. doi: https://doi.org/10.1159/000068563.
Cho H, Wolf KJ, Wolf EJ. Management of ocular inflammation and pain following cataract surgery: focus on bromfenac ophthalmic solution. Clin Ophthalmol. 2009; 3:199-210. doi: https://dx.doi.org/10.2147%2Fopth.s4806
Baklayan GA, Patterson HM, Song CK, Gow JA, McNamara TR. 24-hour evaluation of the ocular distribution of (14)C-labeled bromfenac following topical instillation into the eyes of New Zealand White rabbits. J Ocul Pharmacol Ther. 2008;24(4):392-398. doi: https://doi.org/10.1089/jop.2007.0082.
Lane SS. Nepafenac: a unique nonsteroidal prodrug. Int Ophthalmol Clin. 2006;46(4):13-20. doi: https://doi.org/10.1097/01.iio.0000212129.53019.49.
Walters T, Raizman M, Ernest P,Gayton JL, Lehmann RP. In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac. J Cataract Refract Surg. 2007; 33 (9): 1539-1545. doi: https://doi.org/10.1089/jop.2007.0082.
Roberts CW. Comparison of diclofenac sodium and flurbiprofen for inhibition of surgically induced miosis. J Cataract Refract Surg.1996;22(1):780-787. doi: https://doi.org/10.1016/S0886-3350(96)80162-3.
Gimbel H, Van Westenbrugge J, Cheetham JK, DeGryse R, Garcia CG. Intraocular Availability and Pupillary Effect of Flurbiprofen and Indomethacin During Cataract Surgery. J Cataract Refract Surg. 1996; 22(4): 474-479. doi: https://doi.org/10.1016/s0886-3350(96)80045-9
Solomon KD, Turkalj JW, Whiteside SB, Stewart JA, Apple DJ. Topical 0.5% ketorolac vs. 0.03% flurbiprofen for inhibition of miosis during cataract surgery.Arch Ophthalmol. 1997;115(9):1119-1122. doi: https://doi.org/10.1001/archopht.1997.01100160289004
Atanis R, Tuaño PM, Vicencio J, Martinez JM, Verzosa L. Effect of topical ketorolac tromethamine and topical nepafenac on maintaining pupillary dilation during phacoemulsification. Philipp J Ophthalmol. 2011; 36 (1):23-27.
Sarkar S, Mondal K.K, Roy S.S, Gayen S,Ghosh A and De R.R. Comparison of preoperative nepafenac (0.1%) and flurbiprofen (0.03%) eye drops in maintaining mydriasis during small incision cataract surgery in patients with senile cataract: A randomized, double-blind study. Ind J Pharmacology. 2015;47(5): 491-495. doi: https://dx.doi.org/10.4103%2F0253-7613.165201.
Prakash S, Bhandare B, Satyanarayana V. and Kumar K. A comparative study on efficacy of nepafenac and flurbiprofen in maintenance of intraoperative mydriasis during cataract surgery: an open label randomized controlled trial. Int J Basic Clinic Pharmacol. 2018; 7 (4): 617-621. doi: http://dx.doi.org/10.18203/2319-2003.Ijbcp20181002
Bansal G, Gupta S, Kumar S and Kansal S. Comparison of the effect of topical bromfenac with nepafenac in maintaining mydriasis during cataract surgery. DJO. 2015;26:97-100. doi: http://dx.doi.org/10.7869/djo.146.
Cervantes-CG, Sanchez-Castro YG, Orozco-CM, Mendoza SE, Velasco BC. Inhibition of surgically induced miosis and prevention of postoperative macular edema with nepafenac. Clin Ophthalmol. 2009;3:219-226.
Chen H, Lin H , Chen W, Zhang B, Xiang W, Li J, Chen W Topical 0.1% Bromfenac Sodium for Intraoperative Miosis Prevention and Prostaglandin E2 Inhibition in Femtosecond Laser-Assisted Cataract Surgery. J Ocul Pharmacol Ther. 2017;33(3):193-201. doi: https://doi.org/10.1089/jop.2016.0114.
Kida T, Ogawa T, McNamara TR, Song CK, Gow JA. Evaluations of the human COX-2 Inhibition for amfenac, bromfenac, diclofenac, and ketorolac. Paper presented at: American Society of Cataract and Refractive Surgery Symposium on cataract, IOL, and Refractive Surgery;2007.
Lane SS, Modi SS, Lehmann RP, Holland EJ. Nepafenac ophthalmic suspension 0.1% for the prevention and treatment of ocular inflammation associated with cataract surgery. J Cataract Refract Surg. 2007; 33 (1): 53-58. doi: https://doi.org/10.1016/j.jcrs.2006.08.043.
Stewart WC, Stewart R, Maxwell WA. Preoperative and postoperative clinical evaluation of nepafenac 0.1% ophthalmic suspension for post cataract inflammation. Presented at: American Society of Cataract and Refractive Surgery;2005.
Malik A, Sadafale A, Gupta Y.K and Gupta A. A comparative study of various topical non-steroidal anti-inflammatory drugs to steroid drops for control of post cataract surgery inflammation. Oman J Ophthalmol. 2016;9 (3): 150-156. doi: https://dx.doi.org/10.4103%2F0974-620X.192268.
Silverstein SM, Cable MG, Sadri E, Peace JH, Fong R, Chandler SP, Gow JA, Klier SM, McNamara TR; Once daily dosing of bromfenac ophthalmic solution 0.09% for postoperative ocular inflammation and pain. Curr Med Res Opin. 2011;27(9): 1693-703. doi: https://doi.org/10.1185/03007995.2011.597663
Gaynes BI, Fiscella R. Topical nonsteroidal anti-inflammatory drugs for ophthalmic use: a safety review. Drug Saf. 2002;25(4):233-250. doi: https://doi.org/10.2165/00002018-200225040-00002.
Copyright (c) 2019 Author (s). Published by Siddharth Health Research and Social Welfare Society
This work is licensed under a Creative Commons Attribution 4.0 International License.
OAI - Open Archives Initiative
Therapoid
